Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 43 of the 46 references it cites were found in a registry or an index.
Abstract
Background: Individuals with congenital adrenal hyperplasia (CAH) require glucocorticoid therapy to replace cortisol and to control androgen excess. We sought to evaluate the effects of glucocorticoid therapy on cardiovascular and metabolic outcomes in individuals with CAH. Methods: We searched bibliographical databases through January 2016 for studies evaluating cardiovascular risk factors in individuals with CAH treated with glucocorticoids compared with controls without CAH. We used a random-effects model to synthesize quantitative data. Results: We included 20 observational studies (14 longitudinal, six cross-sectional) with a moderate to high risk of bias. The average dose of glucocorticoids (in hydrocortisone equivalents) was 9 to 26.5 mg/m2/d. In the meta-analysis (416 patients), compared with controls without CAH, individuals with CAH had increased systolic blood pressure [weighted mean difference (WMD), 4.44 mm Hg; 95% CI, 3.26 to 5.63 mm Hg], diastolic blood pressure (WMD, 2.35 mm Hg; 95% CI, 0.49 to 4.20 mm Hg), homeostatic model assessment of insulin resistance (WMD, 0.49; 95% CI, 0.02 to 0.96), and carotid intima thickness (WMD, 0.08 mm; 95% CI, 0.01 to 0.15 mm). No statistically significant differences were noted in fasting blood glucose, insulin level, glucose, or insulin level after 2-hour glucose load or serum lipids. Data on cardiac events were sparse, and most of the literature focused on surrogate outcomes. Conclusion: Individuals with CAH demonstrate a high prevalence of cardiovascular and metabolic risk factors. The current evidence relies on surrogate outcomes. Long-term prospective studies are warranted to assess strategies for reducing cardiovascular risk in individuals with CAH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A meta-analysis of 20 studies of CAH found an increased risk of insulin resistance, elevated blood pressure and carotid intima thickness, although the quality of evidence was low82.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the non-obese patients were similarly affected by hypertension and diabetes as the entire CAH cohort.”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [671]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Obesity was consistently increased in all subgroups while diabetes was increased in females, SV and NC phenotypes and those above 40 years of age.”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [671]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of overweight and obesity are greater in adults with CAH in the UK (360) and Sweden (671) but similar to the general population in the US (217) and France (626,672).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [671]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In another new meta-analysis, investigators found no direct well-controlled evidence of cardiovascular or metabolic morbidity and mortality associated with CAH.”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [41]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We performed a meta-analysis for each of the outcomes of interest using a random-effects model (10).”
(2014) · Medical Entomology and Zoology · Cited by 17,633
Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease
Vasan, R. S., Larson, M. G., Leip, E. P., Evans, J. C., O'Donnell, C. J., Kannel, W. B., & Levy, D. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003417 · Cited by 2,082 · cited 1×
“For example, in the Framingham Heart Study cohort, a stepwise increase in cardiovascular event rates was noted in adult men with higher baseline blood pressure categories (35).”
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationBlood Pressure as a Cardiovascular Risk Factor: Prevention and Treatment
Kannel, W. B. (1996) · JAMA · doi:10.1001/jama.1996.03530440051036 · Cited by 1,230
Blood Pressure, Systolic and Diastolic, and Cardiovascular Risks: US Population Data
Stamler, J. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410050036006 · Cited by 1,015
Neaton, J. D. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.1992.00400130082009 · Cited by 784
Congenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients
Arlt, W., Willis, D. S., Wild, S. H., Krone, N., Doherty, E. J., Hahner, S., Han, T. S., Carroll, P. V., Conway, G. S., Rees, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0917 · Cited by 506 · cited 4×
“with CAH in the UK CAH Adult Study (27, 29, 30), higher rates of hypertension (HTN) were observed in patients with CAH diagnosed late (after 1 year) than in those diagnosed early, and HTN rates were also higher in women treated with glucocorticoids only than in those treated with both glucocorticoids and mineralocorti…”
InfluentialMurad, M. H. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.001 · Cited by 386 · cited 4×
“2018-01862 J Clin Endocrinol Metab, November 2018, 103(11):4097–4103 https://academic.”
InfluentialSelf-citationTherrell, B. L., Berenbaum, S. A., Manter-Kapanke, V., Simmank, J., Korman, K., Prentice, L., Gonzalez, J., & Gunn, S. (1998) · Pediatrics · doi:10.1542/peds.101.4.583 · Cited by 344 · cited 1×
“1% to 1% or even higher depending on ethnicity and race, is usually detected in later childhood, adolescence, or adult life, and it is associated with relatively mild enzyme impairment (4, 5).”
Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia
Finkielstain, G. P., Kim, M. S., Sinaii, N., Nishitani, M., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Hanna, R. M., & Merke, D. P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2102 · Cited by 313 · cited 2×
“In a cross-sectional study (28) of 244 patients with CAH Figure 1.”
Genetics of congenital adrenal hyperplasia
Krone, N., & Arlt, W. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.014 · Cited by 312 · cited 2×
“cases and is characterized by cortisol deficiency, with or without aldosterone deficiency and androgen excess (1, 2).”
The Natural History of Borderline Isolated Systolic Hypertension
Sagie, A., Larson, M. G., & Levy, D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312233292602 · Cited by 288
Falhammar, H., Frisén, L., Hirschberg, A. L., Norrby, C., Almqvist, C., Nordenskjöld, A., & Nordenström, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2093 · Cited by 204 · cited 3×
“, 2015 (31) Sweden Case-control All 588 NA”
InfluentialMallappa, A., Sinaii, N., Kumar, P., Whitaker, M. J., Daley, L.-A., Digweed, D., Eckland, D. J. A., Van Ryzin, C., Nieman, L. K., Arlt, W., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3809 · Cited by 167 · cited 1×
“Promising approaches with new modified-release and pediatric-specific low-dose glucocorticoid formulations might be additional tools that could help in achieving these goals (42).”
Falhammar, H., Filipsson, H., Holmdahl, G., Janson, P.-O., Nordenskjöld, A., Hagenfeldt, K., & Thorén, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1350 · Cited by 167
Charmandari, E., Weise, M., Bornstein, S. R., Eisenhofer, G., Keil, M. F., Chrousos, G. P., & Merke, D. P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8456 · Cited by 164 · cited 1×
“, 2002 (14) Germany Case-control Children 18 Moderate”
Pang, S., Clark, A., Neto, E. C., Giugliani, R., Dean, H., Winter, J., Dhondt, J.-L., Farriaux, J. P., Graters, A., Cacciari, E., et al. (1993) · Screening · doi:10.1016/0925-6164(93)90024-d · Cited by 161 · cited 1×
“Depending on the extent of enzyme impairment, CCAH is subclassified as either salt losing or simple virilizing (3).”
Sartorato, P., Zulian, E., Benedini, S., Mariniello, B., Schiavi, F., Bilora, F., Pozzan, G., Greggio, N., Pagnan, A., Mantero, F., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1711 · Cited by 132 · cited 1×
“, 2007 (15) Italy Case-control Adults 19 Moderate”
Krone, N., Rose, I. T., Willis, D. S., Hodson, J., Wild, S. H., Doherty, E. J., Hahner, S., Parajes, S., Stimson, R. H., Han, T. S., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3343 · Cited by 119 · cited 4×
“with CAH in the UK CAH Adult Study (27, 29, 30), higher rates of hypertension (HTN) were observed in patients with CAH diagnosed late (after 1 year) than in those diagnosed early, and HTN rates were also higher in women treated with glucocorticoids only than in those treated with both glucocorticoids and mineralocorti…”
InfluentialFalhammar, H., Filipsson Nyström, H., Wedell, A., & Thorén, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0877 · Cited by 103 · cited 1×
“, 2011 (20) Sweden Case-control Adults 30 Moderate”
Treatment and health outcomes in adults with congenital adrenal hyperplasia
Han, T. S., Walker, B. R., Arlt, W., & Ross, R. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.239 · Cited by 102 · cited 1×
“In contrast, poor compliance or insufficient glucocorticoid therapy can lead to androgen excess, infertility, and development of adrenal crest tumors (6, 7).”
Völkl, T. M. K., Simm, D., Dötsch, J., Rascher, W., & Dörr, H. G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1069 · Cited by 91
Bonfig, W., Roehl, F.-W., Riedl, S., Dörr, H. G., Bettendorf, M., Brämswig, J., Schönau, E., Riepe, F., Hauffa, B., Holl, R. W., et al. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpv087 · Cited by 84
Subbarayan, A., Dattani, M. T., Peters, C. J., & Hindmarsh, P. C. (2014) · Clinical Endocrinology · doi:10.1111/cen.12265 · Cited by 73 · cited 1×
“, 2014 (24) United Kingdom Case-control Children and adolescents 107 Low”
Williams, R. M., Deeb, A., Ong, K. K., Bich, W., Murgatroyd, P. R., Hughes, I. A., & Acerini, C. L. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03587.x · Cited by 69
Marra, A. M., Improda, N., Capalbo, D., Salzano, A., Arcopinto, M., De Paulis, A., Alessio, M., Lenzi, A., Isidori, A. M., Cittadini, A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1805 · Cited by 67 · cited 1×
“, 2015 (25) Italy Cross-sectional Adolescents 20 Moderate”
Han, T. S., Conway, G. S., Willis, D. S., Krone, N., Rees, D. A., Stimson, R. H., Arlt, W., Walker, B. R., Ross, R. J., & (CaHASE), T. U. K. C. A. H. A. S. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1486 · Cited by 65 · cited 4×
“, 2014 (30) United Kingdom Cross-sectional Adults 199 NA”
InfluentialHarrington, J., Peña, A. S., Gent, R., Hirte, C., & Couper, J. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04309.x · Cited by 46 · cited 3×
“…25 Moderate Mooij et al., 2011 (19) Netherlands Case-control Adults 27 Low Falhammar et al., 2011 (20) Sweden Case-control Adults 30 Moderate Harrington et al., 2012 (21) Australia Case-control Children 14 Low Wasniewska et al., 2013 (22) Italy Cross-sectional Adolescents 18 Moderate Amr et…”
Amr, N. H., Ahmed, A. Y., & Ibrahim, Y. A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0148-8 · Cited by 44 · cited 1×
“, 2014 (23) Egypt Case-control Children 32 Moderate”
Mooij, C. F., Kroese, J. M., Sweep, F. C. G. J., Hermus, A. R. M. M., & Tack, C. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024204 · Cited by 42 · cited 1×
“, 2011 (19) Netherlands Case-control Adults 27 Low”
Ferenczi, A., Garami, M., Kiss, E., Pék, M., Sasvári-Székely, M., Barta, C., Staub, M., Sólyom, J., & Fekete, G. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5835 · Cited by 40 · cited 1×
“1% to 1% or even higher depending on ethnicity and race, is usually detected in later childhood, adolescence, or adult life, and it is associated with relatively mild enzyme impairment (4, 5).”
Moreira, R. P. P., Gomes, L. G., Mendonca, B. B., & Bachega, T. A. S. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044893 · Cited by 38 · cited 1×
“In a Brazilian case-control study (34), HTNwas found in 12% of patients, and heterozygotes for the BclI polymorphism within intron 2 of the glucocorticoid receptor (NR3C1) gene exhibited higher SBP than wild-type subjects.”
Zimmermann, A., Grigorescu-Sido, P., AlKhzouz, C., Patberg, K., Bucerzan, S., Schulze, E., Zimmermann, T., Rossmann, H., Geiss, H.-C., Lackner, K. J., et al. (2010) · Hormone Research in Paediatrics · doi:10.1159/000313368 · Cited by 38 · cited 1×
“, 2010 (17) Romania Case-control Children and adolescents 27 Low”
Wasniewska, M. G., Balsamo, A., Valenzise, M., Manganaro, A., Faggioli, G., Bombaci, S., Conti, V., Ferri, M., Aversa, T., Cicognani, A., et al. (2013) · PubMed · doi:10.3275/8194 · Cited by 37 · cited 1×
“, 2013 (22) Italy Cross-sectional Adolescents 18 Moderate”
Lipid profile in congenital adrenal hyperplasia
Botero, D., Arango, Á. I., Danon, M., & Lifshitz, F. (2000) · Metabolism · doi:10.1053/meta.2000.6261 · Cited by 32 · cited 2×
“…of Included Studies Study ID Country Study Design Age Group Sample Size Overall Methodological Quality Studies included in quantitative synthesis Botero et al., 2000 (13) Colombia Case-control Children 14 Low Charmandari et al., 2002 (14) Germany Case-control Children 18 Moderate Sartorato et…”
Mooij, C. F., Webb, E. A., Claahsen van der Grinten, H. L., & Krone, N. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2016-311910 · Cited by 31 · cited 1×
“Therefore, efforts should be exerted to minimize these possible contributors (41).”
Akyürek, N., Atabek, M. E., Eklioğlu, B. S., & Alp, H. (2015) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.1658 · Cited by 26 · cited 1×
“, 2015 (26) Turkey Case-control Children and adolescents 25 Low”
Cited by
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCongenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationCongenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341
Congenital adrenal hyperplasia
Auer, M. K., Nordenström, A., Lajic, S., & Reisch, N. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01330-7 · Cited by 215
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Metadata
- Authors
- Tamhane, S., Rodriguez-Gutierrez, R., Iqbal, A. M., Prokop, L. J., Bancos, I., Speiser, P. W., & Murad, M. H.
- Affiliations
- Mayo Clinic (US)
- Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
- Corresponding author
- Murad, Mohammad Hassan
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-09-28
- Volume
- 103
- Issue
- 11
- Pages
- 4097-4103
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2892833452
- Cited by
- 123
- References
- 46
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 14 · 2023: 22 · 2022: 23 · 2021: 17 · 2020: 9 · 2019: 7 · 2018: 1
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Endocrine Society (na)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- congenital adrenal hyperplasia, glucocorticoid therapy, cardiovascular risk factors, hypertension, insulin resistance, carotid intima-media thickness, metabolic risk factors, cortisol
- MeSH terms
- Adrenal Hyperplasia, Congenital, Blood Pressure, Cardiovascular Diseases, Cardiovascular System, Endocrinology, Glucocorticoids, Humans, Risk Factors, Prevalence, Practice Guidelines as Topic, Metabolic Syndrome, Carotid Intima-Media Thickness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.